Followers | 4048 |
Posts | 152463 |
Boards Moderated | 3 |
Alias Born | 08/05/2009 |
Friday, October 27, 2023 8:38:56 AM
Recent APLM News
- Biotech Sees Massive Buying Pressure Following Phase 2 Preliminary Data • AllPennyStocks.com • 08/13/2024 02:50:00 PM
- Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting • GlobeNewswire Inc. • 06/04/2024 12:00:00 PM
- Apollomics Announces Presentation at the 2024 BIO International Convention • GlobeNewswire Inc. • 05/29/2024 12:00:00 PM
- Apollomics Announces Private Placement Financing and Addition to Board of Directors • GlobeNewswire Inc. • 05/08/2024 08:05:00 PM
- Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene • GlobeNewswire Inc. • 04/25/2024 12:30:00 PM
- Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting • GlobeNewswire Inc. • 04/10/2024 11:00:00 AM
- Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting • GlobeNewswire Inc. • 04/02/2024 12:00:00 PM
- Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/28/2024 11:00:00 AM
- Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024 • GlobeNewswire Inc. • 03/26/2024 12:00:00 PM
- Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer • GlobeNewswire Inc. • 03/04/2024 12:00:00 PM
- Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/07/2024 12:00:00 PM
- Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency • GlobeNewswire Inc. • 01/19/2024 09:15:00 PM
- Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology Conference • GlobeNewswire Inc. • 01/17/2024 09:30:00 PM
- Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia • GlobeNewswire Inc. • 01/03/2024 12:00:00 PM
- Apollomics to Present at the 2024 Biotech Showcase • GlobeNewswire Inc. • 01/02/2024 09:30:23 PM
- Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation • GlobeNewswire Inc. • 12/04/2023 12:00:00 PM
- Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference • GlobeNewswire Inc. • 11/29/2023 12:30:00 PM
- Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC) • GlobeNewswire Inc. • 11/28/2023 12:00:40 PM
- Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer • GlobeNewswire Inc. • 11/16/2023 01:30:00 PM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM
DBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes • DBGI • Nov 7, 2024 2:16 PM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • SMX • Nov 7, 2024 8:48 AM
Rainmaker Worldwide Inc. (OTC: RAKR) Announces Successful Implementation of 1.6 Million Liter Per Day Wastewater Treatment Project in Iraq • RAKR • Nov 7, 2024 8:30 AM
SBC Medical Group Holdings and MEDIROM Healthcare Technologies Announce Business Alliance • SBC • Nov 7, 2024 7:00 AM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM